Condition
Stasis Dermatitis
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06980961Not ApplicableRecruitingPrimary
Short and Ultra-short-pulse ND: YAG 1064nm Lasers (Omer Smart and Omer Premium) for Stasis Dermatitis
NCT06427733Phase 1CompletedPrimary
Green Banana Peel Extract for Stasis Dermatitis Treatment
NCT04091087Phase 2CompletedPrimary
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
NCT03022786Not ApplicableCompletedPrimary
Improving Value of Care for Patients With Severe Stasis Dermatitis
Showing all 4 trials